Adverum Biotechnologies, Inc.
ADVM
$2.91
-$0.06-2.02%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.00M | 1.00M | 0.00 | 0.00 | 3.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.00M | 1.00M | 0.00 | 0.00 | 3.60M |
| Cost of Revenue | 77.04M | 68.03M | 68.34M | 71.84M | 77.49M |
| Gross Profit | -76.04M | -67.03M | -68.34M | -71.84M | -73.89M |
| SG&A Expenses | 63.12M | 41.02M | 45.02M | 53.71M | 55.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 140.16M | 109.05M | 113.36M | 125.54M | 132.54M |
| Operating Income | -139.16M | -108.05M | -113.36M | -125.54M | -128.94M |
| Income Before Tax | -130.93M | -100.20M | -105.93M | -118.94M | -123.19M |
| Income Tax Expenses | -- | -1.13M | -1.12M | -1.10M | -1.08M |
| Earnings from Continuing Operations | -130.93 | -99.06 | -104.81 | -117.85 | -122.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -130.93M | -99.06M | -104.81M | -117.85M | -122.12M |
| EBIT | -139.16M | -108.05M | -113.36M | -125.54M | -128.94M |
| EBITDA | -135.51M | -104.20M | -108.89M | -120.49M | -123.30M |
| EPS Basic | -6.59 | -6.52 | -8.48 | -10.72 | -12.11 |
| Normalized Basic EPS | -4.12 | -4.15 | -5.37 | -6.77 | -7.64 |
| EPS Diluted | -6.59 | -6.52 | -8.48 | -10.72 | -12.11 |
| Normalized Diluted EPS | -4.12 | -4.15 | -5.37 | -6.77 | -7.64 |
| Average Basic Shares Outstanding | 79.11M | 68.33M | 57.55M | 46.78M | 40.33M |
| Average Diluted Shares Outstanding | 79.11M | 68.33M | 57.55M | 46.78M | 40.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |